Biologics Developability Assessment

As a preclinical CRO specializing in oncology, Alfa Cytology provides comprehensive developability assessment services for a broad range of biologics, including monoclonal antibodies, bispecific antibodies, fusion proteins, ADCs, gene therapy vectors, and nucleic acid therapeutics, covering in silico sequence analysis, physicochemical characterization, non-specific binding evaluation, and stability stress testing. Our platform empowers you to select candidates with the highest probability of successful clinical translation.

Introduction to Biologics Developability Assessment

Developability refers to the potential of a biologic candidate to possess sufficient physicochemical stability, manufacturability, and safety profiles to support clinical development and subsequent commercialization. Unlike small molecule drugs, biologics face distinctly more complex challenges—beyond the primary sequence, higher-order structure, post-translational modification profiles, aggregation propensity, immunogenicity risk, and Fc-mediated effector functions all critically influence ultimate success or failure. These molecular attributes directly impact expression yield, purification behavior, formulation feasibility, in vivo stability, and clinical safety and efficacy. According to published analyses, over 30% of biologic drug failures can be attributed to developability issues, including chemical instability (oxidation, deamidation, isomerization), physical instability (aggregation, high viscosity), and immunogenicity risk, rather than a lack of binding affinity or biological activity. Conducting systematic developability assessment of biologic candidates prior to CMC development and preclinical safety evaluation enables early identification of high-risk liabilities, guides targeted engineering, and provides a scientific foundation for candidate selection. This approach not only reduces the probability of late-stage attrition but also ensures that R&D resources are strategically allocated to molecules with the greatest translational potential, ultimately increasing the likelihood of successful clinical advancement.

Fig. 1 Key factors affecting developability assessment. (Zhang W, et al.; 2022)

Our Services

The core of biologics developability assessment lies in key attributes such as sequence risk analysis, physicochemical properties, immunogenicity risk, stability characteristics, and process feasibility. Our services cover a broad spectrum of biologics modalities, ranging from monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs) to fusion proteins, therapeutic peptides, as well as gene therapy vectors (AAV, lentivirus) and nucleic acid therapeutics (mRNA, siRNA).

By integrating multidimensional data, such as in silico sequence evaluation, expression titer and purity analysis, thermal stability, forced degradation studies, and Fc functional characterization (where applicable), Alfa Cytology enables you to identify candidate molecules with the highest probability of successful clinical translation prior to committing to costly CMC development and preclinical studies, thereby systematically mitigating R&D risks.

Supported Biologics Modalities

We offer customized developability assessment solutions tailored to the structural attributes and development challenges of diverse biologics modalities.

Developability Assessment Strategies by Modality

Tumor Model Library

The value of developability assessment lies in identifying candidate molecules with the greatest potential for clinical translation—but the assessment itself is not the endpoint. Whether a candidate molecule can demonstrate antitumor activity in disease-relevant models is what ultimately determines whether the program moves forward. Alfa Cytology's Tumor Model Library enables your candidates to transition seamlessly from early developability assessment to efficacy validation.

Our model library encompasses:

Areas of Expertise in Oncology

Our biologics developability assessment platform is backed by deep oncology expertise, covering a broad spectrum of solid tumors and hematological malignancies, with extensive experience in the development and validation of novel therapeutics across diverse indications.

Data-driven biologics developability assessment enables early identification of candidates with optimal stability, manufacturability, and safety profiles. At Alfa Cytology, our scientists deliver tailored solutions for your biologics programs, ranging from mAbs to gene therapies. Please contact us to accelerate your biologics development.

For research use only.